Litigation Details for CELGENE CORPORATION v. SYNTHON PHARMACEUTICALS INC. (D.N.J. 2019)
✉ Email this page to a colleague
CELGENE CORPORATION v. SYNTHON PHARMACEUTICALS INC. (D.N.J. 2019)
Docket | ⤷ Try a Trial | Date Filed | 2019-04-12 |
Court | District Court, D. New Jersey | Date Terminated | 2019-05-13 |
Cause | 15:1126 Patent Infringement | Assigned To | Esther Salas |
Jury Demand | None | Referred To | Michael A. Hammer |
Patents | 8,198,262; 8,673,939; 8,735,428; 8,828,427; 9,993,467 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in CELGENE CORPORATION v. SYNTHON PHARMACEUTICALS INC.
Details for CELGENE CORPORATION v. SYNTHON PHARMACEUTICALS INC. (D.N.J. 2019)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-04-12 | 1 | Complaint | States Patent Nos. 8,198,262 (“’262 patent”), 8,673,939 (“’939 patent”), 8,735,428 (“’428 patent”), 8,… claims of the ’262 patent, the ’939 patent, the ’428 patent, and the ’427 patent are invalid and/or …United States Patent Nos. 10,093,647 (the “’647 patent”), 10,093,648 (the “’648 patent”), and 10,093,649… 1. This is an action for patent infringement under the patent laws of the United States, 35 …10,093,649 (the “’649 patent”) (collectively, “the patents-in-suit”) owned by Celgene. | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |